Related Experiment Video

Updated: Jun 8, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Recent advances in managing triple-negative breast cancers

Carmelo Bengala1

  • 1Division of Medical Oncology, Department of Oncology, Hematology and Respiratory Diseases, University Hospital, University of Modena and Reggio Emilia Via del Pozzo, 71 - 41100, Modena Italy.

F1000 Medicine Reports
|October 16, 2010
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks specific targets, making conventional chemotherapy the primary treatment. This review covers current management strategies and recent advancements for TNBC.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Triple-negative breast cancer (TNBC) is a distinct breast cancer subtype.
  • TNBC lacks expression of estrogen receptors, progesterone receptors, and HER2.
  • This necessitates different therapeutic strategies compared to other breast cancer types.

Purpose of the Study:

  • To review the current management of TNBC.
  • To highlight recent advances in TNBC treatment.

Main Methods:

  • Literature review of current clinical practices.
  • Analysis of recent research findings and clinical trials.

Main Results:

  • Conventional cytotoxic chemotherapy remains the primary treatment modality for TNBC.
  • Emerging therapeutic approaches are being investigated and developed.

Conclusions:

  • Effective management of TNBC requires understanding its unique characteristics.
  • Continued research is crucial for improving outcomes in triple-negative breast cancer.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...